Viewpoint: Stroke Prevention in Recent Guidelines for the Management of Patients with Atrial Fibrillation: An Appraisal - 27/09/17
, Carina Blomström-Lundqvist, MD, PhD e, Chern-En Chiang, MD f, A. John Camm, MD gAbstract |
Formal guidelines play an important role in disseminating the best available evidence knowledge and are expected to provide simple and practical recommendations for the most optimal management of patients with various conditions. Such guidelines have important implications for many disease states, which thereby could be more professionally managed in everyday clinical practice by clinicians with divergent educational backgrounds, and also more easily implemented in wards or outpatient clinics, eliminating inequalities in health care management. In this brief Viewpoint we provide an appraisal on the recommendations pertinent to the prevention of atrial fibrillation–related stroke or systemic thromboembolism, as provided in recently published guidelines for the management of this arrhythmia.
El texto completo de este artículo está disponible en PDF.Keywords : Atrial fibrillation, Guidelines, Stroke prevention
Esquema
| Funding: None. |
|
| Conflict of Interest: TSP has received speaker fees from Pfizer, Bayer, and Boehringer Ingelheim; and is on the local scientific advisory board for Boehringer Ingelheim in Serbia. GYHL is a consultant for Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife, and Daiichi-Sankyo; and is a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche, and Daiichi-Sankyo; no fees are received personally. CB-L is on the advisory board for Bayer, Pfizer, Sanofi, Medtronic, Boston, and MSD. C-EC has received honoraria for lectures from AstraZeneca, Bayer, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi, Daiichi-Sankyo, Roche, Servier, Tanabe, TTY, and Takeda; and is on the advisory boards for Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, MSD, Novartis, Pfizer, and Sanofi. AJC is a consultant for Armetheon, Bayer, BMS/Pfizer, Boston Scientific, Biotronik, Medtronic, Boehringer Ingelheim, Daiichi-Sankyo, and St. Jude Medical; and is a speaker for Bayer, BMS/Pfizer, Medtronic, Daiichi-Sankyo, and St. Jude Medical. |
|
| Authorship: All authors had access to the data and a role in writing the manuscript. |
Vol 130 - N° 7
P. 773-779 - juillet 2017 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?
